Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 5/20 | 0.45 |
| ▸ | GSK3B | P49841 | 10/20 | 0.41 |
| ▸ | GSK3A | P49840 | 8/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 2/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15261910 | 1.00 | LPAR1 (0.45) | LPAR1GSK3BGSK3AMAPTLPAR3 | |
| SCHEMBL9915920 | 0.88 | LPAR1 (0.45) | LPAR1MAPTLPAR3CXCR2CXCR1 | |
| SCHEMBL15261885 | 0.88 | LPAR1 (0.45) | LPAR1MAPTLPAR3CXCR2CXCR1 | |
| SCHEMBL9915925 | 0.84 | LPAR1 (0.52) | LPAR1GSK3BGSK3AMAPTLPAR3 | |
| SCHEMBL9915915 | 0.83 | LPAR1 (0.49) | LPAR1LPAR3SLC22A12 | |
| SCHEMBL12989242 | 0.80 | LPAR1 (0.74) | LPAR1LPAR3 | |
| SCHEMBL12989240 | 0.80 | LPAR1 (0.74) | LPAR1LPAR3 | |
| SCHEMBL9899613 | 0.79 | ROCK2 (0.43) | GSK3BGSK3AMAPTSLC22A12 | |
| SCHEMBL9899954 | 0.77 | LPAR1 (0.67) | LPAR1LPAR3 | |
| SCHEMBL15261662 | 0.77 | LPAR1 (0.67) | LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9272990-B2 | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis | AMIRA PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| US-9272990-B2 | Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis | AMIRA PHARMACEUTICALS, INC. (US) | 2016-03-01 | — | — | US | disclosed |
| CN-103347510-B | Lysophosphatidic acid receptor antagonists and their use in the treatment of fibrosis | AMIRA PHARMACEUTICALS, INC. (US) | 2015-11-25 | — | — | CN | disclosed |
| EP-2648714-B1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2015-11-18 | — | — | EP | disclosed |
| EP-2648714-B1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF | AMIRA PHARMACEUTICALS INC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-20130253004-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT FIBROSIS | AMIRA PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130253004-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT FIBROSIS | AMIRA PHARMACEUTICALS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| WO-2012078593-A2 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND USES THEREOF | AMIRA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130253004-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND THEIR USE IN THE TREATMENT FIBROSIS | LPAR2, LPAR1, LPAR4 | LPAR1 2/4885GSK3B 1679/4885GSK3A 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.